Basalin(R)(insulin glargine injection)

Basalin(R)(insulin glargine injection)

Products

Information

Basalin(R) is an insulin glargine injection developed and produced independently by Gan & Lee Pharmaceuticals. It was launched in China in 2005 and has been approved in almost 20 countries globally. As a long-acting biosimilar insulin, Basalin(R) is able to stablely control human blood sugar within 24 hours for the treatment of diabetes.
All Categories
Biosimilars
Main Categories
Biopharmaceutical ProductsFinished Dosage Forms (Products)
Distribution Areas
AfricaMiddle East Region (e.g. UAE)Central America (e.g. Mexico)East Asia (e.g. China, Japan, Korea)South America (e.g. Brazil, Colombia)South Asia (e.g. India, Pakistan, Sri Lanka)South East Asia (e.g. Thailand, Philippines, Singapore)
Gan & Lee PharmaceuticalsFounded in 1998, Gan & Lee Pharmaceuticals has successfully developed the first Chinese domestic insulin analog. The company has become one of the main suppliers of insulin in China and now strives to broaden its global coverage in the field of diabetes diagnosis and treatment. Headquartered in the Tongzhou Economic Development Area, Beijing, China, Gan & Lee has state-of-the-art buildings and GMP facilities. In 2014, it established a US subsidiary in New Jersey, and in 2019, Gan & Lee selected Linyi City, Shandong, China, to become its second domestic drug product...

Log in

See all the content and easy-to-use features by logging in or registering!